Literature DB >> 20056838

Involvement of CYR61 and CTGF in the fascin-mediated proliferation and invasiveness of esophageal squamous cell carcinomas cells.

Jian-Jun Xie1, Li-Yan Xu, Jian-Yi Wu, Zhong-Ying Shen, Qing Zhao, Ze-Peng Du, Zhuo Lv, Wei Gu, Feng Pan, Xiu-E Xu, Dong Xie, En-Min Li.   

Abstract

Fascin is overexpressed in esophageal squamous cell [corrected] carcinoma (ESCC) and involved in the proliferation and invasiveness of ESCC cells. In this study, we retrospectively examined the expression of fascin in ESCC samples by immunohistochemistry and revealed that overexpression of fascin was related to poor patient survival. RNAi-mediated knockdown of fascin in ESCC cells significantly inhibited cell proliferation and invasiveness, whereas forced expression of fascin in immortalized esophageal epithelial cells accelerated cell proliferation and invasiveness. To explore the underlying mechanism, cDNA microarray was performed to identify the differential gene expression profiles between a fascin-depleted cell line by RNAi and the corresponding control ESCC cells. Results showed that 296 genes were differentially expressed on fascin depletion. In this study, we focused on two down-regulated genes: CYR61 and CTGF. We found that restored expression of either CYR61 or CTGF led to a recovery of the suppression of cellular proliferation and invasiveness induced by down-regulation of fascin expression; the protein level of CYR61 and CTGF were up-regulated in ESCCs and their expression pattern correlated with fascin overexpression. Finally, analysis of signal transduction revealed that fascin affected the expressions of CYR61 and CTGF through transforming growth factor (TGF)-beta pathway. Taken together, we propose that fascin regulates the proliferation and invasiveness of ESCC cells by modulating the expression of CTGF and CYR61 via TGF-beta pathway.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20056838      PMCID: PMC2808098          DOI: 10.2353/ajpath.2010.090118

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  43 in total

Review 1.  Fascins, and their roles in cell structure and function.

Authors:  Nina Kureishy; Vasileia Sapountzi; Soren Prag; N Anilkumar; Josephine Clare Adams
Journal:  Bioessays       Date:  2002-04       Impact factor: 4.345

2.  Elevated levels of connective tissue growth factor, WISP-1, and CYR61 in primary breast cancers associated with more advanced features.

Authors:  D Xie; K Nakachi; H Wang; R Elashoff; H P Koeffler
Journal:  Cancer Res       Date:  2001-12-15       Impact factor: 12.701

Review 3.  Making sense of latent TGFbeta activation.

Authors:  Justin P Annes; John S Munger; Daniel B Rifkin
Journal:  J Cell Sci       Date:  2003-01-15       Impact factor: 5.285

4.  Clinicopathological significance of human macrophage metalloelastase expression in esophageal squamous cell carcinoma.

Authors:  Yongzeng Ding; Yutaka Shimada; Manuel J Gorrin-Rivas; Atsushi Itami; Zhigang Li; Tao Hong; Masato Maeda; Izumi Komoto; Atsushi Kawabe; Junichi Kaganoi; Masayuki Imamura
Journal:  Oncology       Date:  2002       Impact factor: 2.935

5.  Cyr61, a member of CCN family, is a tumor suppressor in non-small cell lung cancer.

Authors:  X Tong; D Xie; J O'Kelly; C W Miller; C Muller-Tidow; H P Koeffler
Journal:  J Biol Chem       Date:  2001-10-11       Impact factor: 5.157

Review 6.  The role of thrombospondin-1 in tumor progression.

Authors:  I Sargiannidou; J Zhou; G P Tuszynski
Journal:  Exp Biol Med (Maywood)       Date:  2001-09

7.  Ovarian carcinomas: CCN genes are aberrantly expressed and CCN1 promotes proliferation of these cells.

Authors:  Sigal Gery; Dong Xie; Dong Yin; Hani Gabra; Carl Miller; Heming Wang; Diane Scott; William S Yi; Miriam L Popoviciu; Johathan W Said; H Phillip Koeffler
Journal:  Clin Cancer Res       Date:  2005-10-15       Impact factor: 12.531

8.  Pattern of recurrence following complete resection of esophageal carcinoma and factors predictive of recurrent disease.

Authors:  Christophe Mariette; Jean-Michel Balon; Guillaune Piessen; Sylvain Fabre; Isabelle Van Seuningen; Jean-Pierre Triboulet
Journal:  Cancer       Date:  2003-04-01       Impact factor: 6.860

9.  Fascin, an actin-bundling protein, modulates colonic epithelial cell invasiveness and differentiation in vitro.

Authors:  Aida U Jawhari; Andrea Buda; Michelle Jenkins; Khurram Shehzad; Catherine Sarraf; Masao Noda; Michael J G Farthing; Massimo Pignatelli; Josephine C Adams
Journal:  Am J Pathol       Date:  2003-01       Impact factor: 4.307

10.  Stimulation of fascin spikes by thrombospondin-1 is mediated by the GTPases Rac and Cdc42.

Authors:  J C Adams; M A Schwartz
Journal:  J Cell Biol       Date:  2000-08-21       Impact factor: 10.539

View more
  25 in total

1.  Specificity protein 1 regulates fascin expression in esophageal squamous cell carcinoma as the result of the epidermal growth factor/extracellular signal-regulated kinase signaling pathway activation.

Authors:  Xiao-Feng Lu; En-Min Li; Ze-Peng Du; Jian-Jun Xie; Zhang-Yan Guo; Shu-Ying Gao; Lian-Di Liao; Zhong-Ying Shen; Dong Xie; Li-Yan Xu
Journal:  Cell Mol Life Sci       Date:  2010-05-26       Impact factor: 9.261

2.  Fascin expression predicts an aggressive clinical course in patients with advanced breast cancer.

Authors:  Kyueng-Whan Min; Seoung Wan Chae; Dong-Hoon Kim; Sung-Im DO; Kyungeun Kim; Hyun Joo Lee; Jin Hee Sohn; Jung-Soo Pyo; Dong Hyun Kim; Sukjoong Oh; Seon Hyeong Choi; Yong Lai Park; Chan Heun Park
Journal:  Oncol Lett       Date:  2015-05-08       Impact factor: 2.967

3.  Cytoplasmic HDPR1 is involved in regional lymph node metastasis and tumor development via beta-catenin accumulation in esophageal squamous cell carcinoma.

Authors:  Jian Hou; En-Min Li; Jin-Hui Shen; Zhi-Yong Wu; Xiu-E Xu; Jian-Yi Wu; Jian Shen; Ming-Zhou Guo; Li-Yan Xu
Journal:  J Histochem Cytochem       Date:  2011-04-27       Impact factor: 2.479

4.  Evaluation of tumor metastasis-associated markers for molecular classification in patients with esophageal squamous cell carcinoma.

Authors:  Jun-Xing Huang; Juan Yao; Mao-Song Lin; Mei Lin; Wei Xiao; Hong Yu; Ping Chen; Rong-Yu Qian
Journal:  Int J Clin Exp Med       Date:  2015-09-15

5.  Downregulation of VGLL4 in the progression of esophageal squamous cell carcinoma.

Authors:  Wei Jiang; Feng Yao; Jing He; Bihong Lv; Wentao Fang; Weidong Zhu; Guangming He; Jianzhong Chen; Jianming He
Journal:  Tumour Biol       Date:  2014-10-30

6.  Phosphorylation of fascin decreases the risk of poor survival in patients with esophageal squamous cell carcinoma.

Authors:  Qing Zhao; Jin-Hui Shen; Zhong-Ying Shen; Zhi-Yong Wu; Xiu-E Xu; Jian-Jun Xie; Jian-Yi Wu; Qiao Huang; Xiao-Feng Lu; En-Min Li; Li-Yan Xu
Journal:  J Histochem Cytochem       Date:  2010-08-16       Impact factor: 2.479

7.  Fascin expression in dendritic cells and tumor epithelium in thymoma and thymic carcinoma.

Authors:  Junichiro Sato; Masachika Fujiwara; Tomohiro Kawakami; Ayumi Sumiishi; Seiji Sakata; Atsuhiko Sakamoto; Atsushi Kurata
Journal:  Oncol Lett       Date:  2011-08-17       Impact factor: 2.967

8.  Epigenetic silencing of HOPX promotes cancer progression in colorectal cancer.

Authors:  Hiroshi Katoh; Keishi Yamashita; Mina Waraya; Ofer Margalit; Akira Ooki; Hideaki Tamaki; Hiroyuki Sakagami; Kenichi Kokubo; David Sidransky; Masahiko Watanabe
Journal:  Neoplasia       Date:  2012-07       Impact factor: 5.715

9.  The up-regulation of cysteine-rich protein 61 induced by transforming growth factor beta enhances osteosarcoma cell migration.

Authors:  Jun Chen; Yang Song; Jing Yang; Li Gong; Peng Zhao; Yong Zhang; Haichuan Su
Journal:  Mol Cell Biochem       Date:  2013-09-14       Impact factor: 3.396

10.  Prognostic significance of FSCN family in multiple myeloma.

Authors:  Cong Deng; Chaozeng Si; Xu Ye; Qiang Zhou; Tiansheng Zeng; Zeyong Huang; Wenhui Huang; Pei Zhu; Qingfu Zhong; Zhihua Wu; Huoyan Zhu; Qing Lin; Wenjuan Zhang; Lin Fu; Yongjiang Zheng; Tingting Qian
Journal:  J Cancer       Date:  2021-01-30       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.